Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies

Authors: Haiqing Luo, Hongjiao Li, Na Yao, Liren Hu, Taiping He

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

Metastasis-associated protein 1 (MTA1) is a molecular marker in various solid tumors that has recently been investigated. The prognostic significance of MAT1 expression remains controversial. In this work, we aimed to determine the relationship between immunohistochemistry-detected MAT1 expression and survival of patients with solid tumors by conducting a meta-analysis of cohort studies. Relevant studies were identified via an electronic database search updated on October 28, 2013. We included cohort studies that reported hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) to determine the association of high MTA1 expression with overall survival (OS) and clinicopathological characteristics. Heterogeneity was quantified using I 2 statistics, and publication bias was evaluated using funnel plots. Sensitivity analysis was conducted to evaluate the robustness of meta-analysis findings. We identified 16 cohort studies that focused on MTA1 overexpression and prognosis involving 2,253 cancer patients. Overall, the combined HR for OS was 1.85 (95 % CI: 1.55–2.28, P < 0.001). Omission of any single study had no significant effect on the pooled HR estimate. When the studies were stratified by tumor type, similar results of poor prognosis were observed in non-small cell lung cancer (HR = 2.05, 95 % CI: 1.14–3.68, P = 0.016) and esophageal squamous cell carcinoma (HR = 1.86, 95 % CI: 1.44–2.39, P < 0.001). Moreover, multivariate survival analysis showed that MTA1 overexpression was an independent predictor of poor prognosis (HR = 1.90, 95 % CI: 1.53–2.37, P < 0.001). In addtional, MTA1 overexpression was significantly associated with tumor size (OR = 2.72, 95 % CI = 1.44–5.14, P = 0.002), tumor stage (OR = 2.44, 95 % CI = 1.67–3.57, P < 0.001), depth of invasion (OR = 2.63, 95 % CI = 1.74–3.97, P < 0.001), and lymph node metastasis (OR = 2.57, 95 % CI = 1.57–4.19, P < 0.001). However, when age, sex, and tumor differentiation were considered, no obvious association was observed. This study provides a comprehensive examination of the literature available on the association of MTA1 overexpression with OS and some clinicopathological features in solid tumors. Meta-analysis results provide evidence that MTA1 may be a new indicator of poor cancer prognosis. Considering the limitations of the eligible studies, other large-scale prospective trials must be conducted to clarify the prognostic value of MTA1 in predicting cancer survival.
Literature
1.
Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988;7:143–88.CrossRefPubMed
2.
Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26:215–27.CrossRefPubMed
3.
Li SH, Tian H, Yue WM, Li L, Li WJ, Chen ZT, et al. Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol. 2011;18:2048–56.CrossRefPubMed
4.
Li SH, Wang Z, Liu XY. Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World J Surg. 2009;33:1876–81.CrossRefPubMed
5.
Deng X, Du L, Wang C, Yang Y, Li J, Liu H, et al. Close association of metastasis-associated protein 1 overexpression with increased angiogenesis and poor survival in patients with histologically node-negative gastric cancer. World J Surg. 2013;37:792–8.CrossRefPubMed
6.
Higashijima J, Kurita N, Miyatani T, Yoshikawa K, Morimoto S, Nishioka M, et al. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol Rep. 2011;26:343–8.PubMed
7.
Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929–36.CrossRefPubMed
8.
Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1–9.CrossRefPubMed
9.
Liu T, Yang M, Yang S, Ge T, Gu L, Lou G. Metastasis-associated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer. Hum Pathol. 2013;44:2275–81.CrossRefPubMed
10.
Tong D, Heinze G, Schremmer M, Schuster E, Czerwenka K, Leodolter S, et al. Expression of the human MTA1 gene in breast cell lines and in breast cancer tissues. Oncol Res. 2007;16:465–70.CrossRefPubMed
11.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
12.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralCrossRefPubMed
13.
Maxwell L, Santesso N, Tugwell PS, Wells GA, Judd M, Buchbinder R. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol. 2006;33:2304–11.PubMed
14.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Ottawa Health Research Institute Web site. 2012.
15.
Wang J, Li C, Tao H, Cheng Y, Han L, Li X, et al. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. PLoS One. 2013;8:e77950.PubMedCentralCrossRefPubMed
16.
17.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
18.
19.
Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, et al. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer. 2013;119:2239–46.CrossRefPubMed
20.
Zhang H. zhang YM, Wang Z, Liu XY, Chen G, Liu FY. Expression of metastasis-associated gene 1 (MTAI) protein and its association with the prognosis of stage I nonsmall cell lung cancer. Tumor. 2010;30:881–5.
21.
Song L, Wang Z, Liu XY, Chen G, Liu FY. Investigation of the expression of MTA1 protein and its relationship to the prognosis in squamous cell carcinoma of the esophagus after esophagectomy. Zhonghua Xiong Wai Ke Za Zhi. 2010;26:343–6.
22.
Jin YJ, Chung YH, Kim JA, Park WH, Lee D, Seo DD, et al. Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Dig Dis Sci. 2012;57:2917–23.CrossRefPubMed
23.
Deng Y, Zhou D, Zeng L. Expression and significance of MTA1 and RECK gene in nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;25:534–8.PubMed
24.
Dias SJ, Zhou X, Ivanovic M, Gailey MP, Dhar S, Zhang L, et al. Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Sci Rep. 2013;3:ep02331.CrossRef
25.
Yu CH, Chen HH, Wang JT, Liu BY, Wang YP, Sun A, et al. Nuclear expression of metastasis-associated protein 1 (MTA1) is inversely related to progression of oral squamous cell carcinoma in Taiwan. J Dental Sci. 2007;2:1–10.
26.
Cheng CW, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, et al. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol. 2012;19:4129–39.CrossRefPubMed
27.
Deng YF, Zhou DN, Ye CS, Zeng L, Yin P. Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. Ann Otol Rhinol Laryngol. 2012;121:457–65.CrossRefPubMed
28.
Hamatsu T, Rikimaru T, Yamashita Y, Aishima S, Tanaka S, Shirabe K, et al. The role of MTA1 gene expression in human hepatocellular carcinoma. Oncol Rep. 2003;10:599–604.PubMed
29.
Lin C, Chen H, Wu M, Yang G, Dai J, Hu S. Expression of tumor metastasis gene MTA 1 in hepatocellular carcinoma: clinical implications. Zhonghua Wai Ke Za Zhi. 2000;38:915–7.PubMed
30.
Chen YT, Xu YC, Huang GC, Yin HL, Yu B, Chen LB. Expression of MTA1 protein in non-small cell lung cancer and its association with the prognosis of the disease. J Med Postgra. 2013;26:717–20.
31.
Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, et al. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006;95:7–12.CrossRefPubMed
32.
Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer. 2004;110:362–7.CrossRefPubMed
33.
Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97:374–9.CrossRefPubMed
34.
Zhang N, Zhang Q, Wang E, Qiu X. Relationship between metastasis-associated protein 1 expression and metastasis and prognosis in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2007;10:279–83.PubMed
35.
Zhu X, Guo Y, Li X, Ding Y, Chen L. Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5:1159–66.CrossRefPubMed
36.
Han XY, Qian HL, Lin C, Zhang XY, Liang X, Fu M, et al. The expression and clinical significance of MTA1 protein in cervical cancers. Shi Yong Fu Chan Ke Za Zhi. 2011;27:511–4.
37.
Yu Y, Wang Z, Zhang MY, Liu XY, Zhang H. Relation between prognosis and expression of metastasis-associated protein 1 in stage I non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2011;12:166–9.CrossRefPubMed
38.
Li WF, Liu N, Cui RX, He QM, Chen M, Jiang N, et al. Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. J Transl Med. 2012;10:78.PubMedCentralCrossRefPubMed
39.
Li SH, Tian H, Yue WM, Li L, Gao C, Li WJ, et al. Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World J Surg. 2012;36:623–31.CrossRefPubMed
40.
Prisco MG, Zannoni GF, De Stefano I, Vellone VG, Tortorella L, Fagotti A, et al. Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Hum Pathol. 2012;43:282–8.CrossRefPubMed
41.
Song L, Wang Z, Liu X. MTA1: a prognosis indicator of postoperative patients with esophageal carcinoma. Thorac Cardiovasc Surg. 2013;61:479–85.CrossRefPubMed
42.
Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003;30:30–7.CrossRefPubMed
43.
Yan C, Wang H, Toh Y, Boyd DD. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem. 2003;278:2309–16.CrossRefPubMed
44.
Hofer MD, Menke A, Genze F, Gierschik P, Giehl K. Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer. 2004;90:455–62.PubMedCentralCrossRefPubMed
Metadata
Title
Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies
Authors
Haiqing Luo
Hongjiao Li
Na Yao
Liren Hu
Taiping He
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1772-9

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Research Article

Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer

Research Article

APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women

Research Article

Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies

Research Article

Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker

Research Article

Aberrant expression of DPPA2 and HIWI genes in colorectal cancer and their impacts on poor prognosis

Research Article

Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits